Maternal Screen First Trimester – Dual Marker / Double Marker

The Double Marker serves as an essential prenatal blood screening typically advised for pregnant women between 11th and 14th week of gestation. The test helps medical professionals to evaluate the risk of chromosomal disorders affecting the fetus such as Down syndrome (Trisomy 21) and Edward syndrome (Trisomy 18).

Dual Marker / Double Marker Test

The test determines the concentration of two key biochemical markers in maternal blood.

• Free Beta-hCG (human chorionic gonadotropin) – a hormone secreted by the placenta
• PAPP-A (Pregnancy-Associated Plasma Protein A) – a protein that plays a role in fetal growth and development

The fetus faces a higher chance of developing chromosomal or genetic disorders when either substance shows abnormal levels. While the Double Marker Test serves as an important screening tool, it is not a conclusive diagnostic test, so healthcare providers may suggest NIPT or amniocentesis for additional testing when required.

The Maternal Screen First Trimester – Dual Marker / Double Marker requires an NT (Nuchal Translucency) scan to achieve better risk evaluation.

This test is recommended for:

• All pregnant women during the first trimester
• Women above 35 or those with a family history of genetic conditions
• Individuals with IVF or assisted conception pregnancies

Dual Marker / Double Marker screening service is available today at UniQ Pathlab, offering fast and reliable testing with free home specimen collection and prompt report delivery to help you make informed decisions for safe and healthy pregnancy.